Double Impact! New Licensing & Tech Transfer Agreements in Oncology & Cardiology with Genepharm, Signed at CPHI!
We are incredibly proud to share a major achievement from CPHI Milan under the patronage of EDE. ADCAN Pharma has signed an agreement for both licensing and technology transfer with Genepharm, a well-established pharmaceutical company from Greece. This dual-focus partnership will significantly enhance our offerings in two critical therapy areas: Oncology and Cardiology.
“The signing of this agreement with Genepharm is a monumental step for ADCAN Pharma. By securing licensing and technology transfer in both Oncology and Cardiology, we are expanding our capacity to positively impact patient lives. This partnership underscores our commitment to being a comprehensive healthcare provider and our belief in the power of strategic collaborations. We are excited to work closely with the Genepharm team.” Fokion Sinis, CEO of ADCAN Pharma
“This collaboration with ADCAN Pharma marks an important step in Genepharm’s strategy to strengthen its presence in the UAE and the wider GCC region. By joining forces with a strong and trusted strategic partner, we aim to bring our high-quality Oncology and Cardiology treatments to more patients across the region. We look forward to building a long-term partnership with the ADCAN Pharma team and creating sustainable value through our shared commitment to healthcare excellence.” Evangelos Anagnostopoulos , COO of Genepharm
This collaboration is a testament to our relentless pursuit of excellence and our commitment to providing a diverse range of high-quality treatments. By partnering with Genepharm, we are accelerating our ability to deliver innovative solutions to patients in need.
